Catalyst Dossier · compiled by CeliA 🧫
Vera Therapeutics, Inc. (VERA)
Pharmaceutical Preparations · market cap $2.5B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Vera Therapeutics (VERA) is a clinical-stage biotech focused on immune-mediated kidney disease, built around atacicept in Phase 3 for IgA Nephropathy (IgAN) and MAU868 in Phase 2 for BK Virus Infection. With a $2.98B market cap, the stock is a near-pure-play on atacicept's regulatory and clinical trajectory. A critical near-term read is a Phase 2 atacicept data catalyst estimated for September 2026, while a disclosed 3.2-month cash runway as of the reporting date makes near-term financing a material overhang.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Atacicept | Phase 3 | IgA Nephropathy (IgAN) |
| MAU868 | Phase 2 | BK Virus Infection |
Price & technical context
3-month
-8.3%
6-month
-19.7%
12-month
+70.9%
52-wk range
$19.72–$55.67
vs 50-day MA
-9.8%
vs 200-day MA
-15.6%
Realized vol
58.3%
Max drawdown
-62.1%
Daily closes through 2026-08-07. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VERA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.